|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen MS, Peng ZW, Xu L, Zhang YJ, Liang HH
and Li JQ: Role of radiofrequency ablation in the treatment of
hepatocellular carcinoma: experience of a cancer center in China.
Oncology. 81(Suppl 1): S100–S104. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rossi L, Zoratto F, Papa A, et al: Current
approach in the treatment of hepatocellular carcinoma. World J
Gastrointest Oncol. 2:348–359. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shimozawa N and Hanazaki K: Longterm
prognosis after hepatic resection for small hepatocellular
carcinoma. J Am Coll Surg. 198:356–365. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang CH, Chau GY, Lui WY, Tsay SH, King
KL and Wu CW: Long-term results of hepatic resection for
hepatocellular carcinoma originating from the noncirrhotic liver.
Arch Surg. 139:320–326. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Greten TF, Manns MP and Korangy F:
Immunotherapy of HCC. (Review). Rev Recent Clin Trials. 3:31–39.
2008. View Article : Google Scholar
|
|
7
|
Caballero OL and Chen YT: Cancer/testis
(CT) antigens: potential targets for immunotherapy. Cancer Sci.
100:2014–2021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hofmann O, Caballero OL, Stevenson BJ, et
al: Genome-wide analysis of cancer/testis gene expression. Proc
Natl Acad Sci USA. 105:20422–20427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gnjatic S, Nishikawa H, Jungbluth AA, et
al: NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer
Res. 95:1–30. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen YT, Scanlan MJ, Sahin U, et al: A
testicular antigen aberrantly expressed in human cancers detected
by autologous antibody screening. Proc Natl Acad Sci USA.
94:1914–1918. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oba-Shinjo SM, Caballero OL, Jungbluth AA,
et al: Cancer-testis (CT) antigen expression in medulloblastoma.
Cancer Immun. 8:72008.
|
|
12
|
Kim SH, Lee S, Lee CH, et al: Expression
of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell
lung carcinomas and their relationship with immune cell
infiltration. Lung. 187:401–411. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang XY, Chen HS, Luo S, Zhang HH, Fei R
and Cai J: Comparisons for detecting NY-ESO-1 mRNA expression
levels in hepatocellular carcinoma tissues. Oncol Rep. 21:713–719.
2009.PubMed/NCBI
|
|
14
|
Grigoriadis A, Caballero OL, Hoek KS, et
al: CT-X antigen expression in human breast cancer. Proc Natl Acad
Sci USA. 106:13493–13498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Svobodová S, Browning J, MacGregor D, et
al: Cancer-testis antigen expression in primary cutaneous melanoma
has independent prognostic value comparable to that of Breslow
thickness, ulceration and mitotic rate. Eur J Cancer. 47:460–469.
2011.
|
|
16
|
Jäger E, Karbach J, Gnjatic S, et al:
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral
and cellular NY-ESO-1-specific immune responses in cancer patients.
Proc Natl Acad Sci USA. 103:14453–14458. 2006.PubMed/NCBI
|
|
17
|
Bender A, Karbach J, Neumann A, et al: LUD
00-009: phase 1 study of intensive course immunization with
NY-ESO-1 peptides in HLA-A2 positive patients with
NY-ESO-1-expressing cancer. Cancer Immun. 7:162007.PubMed/NCBI
|
|
18
|
Odunsi K, Qian F, Matsuzaki J, et al:
Vaccination with an NY-ESO-1 peptide of HLA class I/II
specificities induces integrated humoral and T cell responses in
ovarian cancer. Proc Natl Acad Sci USA. 104:12837–12842. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nicholaou T, Ebert L, Davis ID, et al:
Directions in the immune targeting of cancer: lessons learned from
the cancer-testis Ag NY-ESO-1. Immunol Cell Biol. 84:303–317. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kakimi K, Isobe M, Uenaka A, et al: A
phase I study of vaccination with NY-ESO-1f peptide mixed with
Picibanil OK-432 and Montanide ISA-51 in patients with cancers
expressing the NY-ESO-1 antigen. Int J Cancer. 129:2836–2846. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Engell-Noerregaard L, Hansen TH, Andersen
MH, Thor Straten P and Svane IM: Review of clinical studies on
dendritic cell-based vaccination of patients with malignant
melanoma: assessment of correlation between clinical response and
vaccine parameters. Cancer Immunol Immunother. 58:1–14. 2009.
View Article : Google Scholar
|
|
22
|
Ladhams A, Schmidt C, Sing G, et al:
Treatment of non-resectable hepatocellular carcinoma with
autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol.
17:889–896. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang W, Xiao G, Zhang M, Xie D, Guo A and
Wen J: The prokaryotic expression, purification and preliminary
application of human NY-ESO-1 gene. Zhongguo Kang Ai Xie Hui.
32:626–629. 2005.(In Chinese).
|
|
24
|
Li DY, Gu C, Min J, Chu ZH and Ou QJ:
Maturation induction of human peripheral blood mononuclear
cell-derived dendritic cells. Exp Ther Med. 4:131–134.
2012.PubMed/NCBI
|
|
25
|
Della Bella S, Nicola S, Riva A, Biasin M,
Clerici M and Villa ML: Functional repertoire of dendritic cells
generated in granulocyte macrophage-colony stimulating factor and
interferon-alpha. J Leukoc Biol. 75:106–116. 2004.
|
|
26
|
Wang XH, Qin Y, Hu MH and Xie Y: Dendritic
cells pulsed with gp96-peptide complexes derived from human
hepatocellular carcinoma (HCC) induce specific cytotoxic T
lymphocytes. Cancer Immunol Immunother. 54:971–980. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pan K, Zhao JJ, Wang H, et al: Comparative
analysis of cytotoxic T lymphocyte response induced by dendritic
cells loaded with hepatocellular carcinoma-derived RNA or cell
lysate. Int J Biol Sci. 6:639–648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cao DY, Yang JY, Yue SQ, et al:
Comparative analysis of DC fused with allogeneic hepatocellular
carcinoma cell line HepG2 and autologous tumor cells as potential
cancer vaccines against hepatocellular carcinoma. Cell Immunol.
259:13–20. 2009. View Article : Google Scholar
|
|
29
|
Rinaldi M, Iurescia S, Fioretti D,
Ponzetto A and Carloni G: Strategies for successful vaccination
against hepatocellular carcinoma. Int J Immunopathol Pharmacol.
22:269–277. 2009.PubMed/NCBI
|
|
30
|
Gedye C, Quirk J, Browning J, et al:
Cancer/testis antigens can be immunological targets in clonogenic
CD133+ melanoma cells. Cancer Immunol Immunother.
58:1635–1646. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Milne K, Barnes RO, Girardin A, et al:
Tumor-infiltrating T cells correlate with NY-ESO-1-specific
autoantibodies in ovarian cancer. PLoS One. 3:e34092008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Odunsi K, Matsuzaki J, Karbach J, et al:
Efficacy of vaccination with recombinant vaccinia and fowlpox
vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma
patients. Proc Natl Acad Sci USA. 109:5797–5802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kawada J, Wada H, Isobe M, et al:
Heteroclitic serological response in esophageal and prostate cancer
patients after NY-ESO-1 protein vaccination. Int J Cancer.
130:584–592. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Korangy F, Ormandy LA, Bleck JS, et al:
Spontaneous tumor-specific humoral and cellular immune responses to
NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res.
10:4332–4341. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luo G, Huang S, Xie X, et al: Expression
of cancer-testis genes in human hepatocellular carcinomas. Cancer
Immun. 2:112002.PubMed/NCBI
|
|
36
|
Perez D, Hauswirth F, Jäger D, et al:
Protein expression of cancer testis antigens predicts tumor
recurrence and treatment response to imatinib in gastrointestinal
stromal tumors. Int J Cancer. 128:2947–2952. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu H, Gu N, Liu ZB, et al: NY-ESO-1
expression in hepatocellular carcinoma: A potential new marker for
early recurrence after surgery. Oncol Lett. 3:39–44.
2012.PubMed/NCBI
|
|
38
|
Bujas T, Marusic Z, Peric Balja M, Mijic
A, Kruslin B and Tomas D: MAGE-A3/4 and NY-ESO-1 antigens
expression in metastatic esophageal squamous cell carcinoma. Eur J
Histochem. 55:e72011. View Article : Google Scholar : PubMed/NCBI
|
